Lanifibranor Reduces Disease Activity in Nonalcoholic Steatohepatitis
In phase 2b trial, more patients with active NASH had reduction in disease activity score with lanifibranor versus placebo
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.